Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesEvaxion Biotech AS

Evaxion Biotech AS

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
3.0 USD 0.24 ( 8.70%)
Last update at 2026-11-06T21:00:00Z
VOLUME
182813
Market Cap
27.43M

Momentum Score

…

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.71
Low
3.21
High
52 Week Price Range
2.77
Low
12.15
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Evaxion Biotech AS is a clinical-stage Danish biotech that uses artificial intelligence and computational immunology to develop immunotherapies and vaccines for cancer and infectious diseases. Long-term growth drivers include clinical trial progress, partnerships to scale development, and the platform's potential to accelerate antigen discovery, which may benefit from broader indications and commercialization opportunities.

Principal investment risks include clinical and regulatory setbacks, limited revenue and financing needs, intense competition in immuno-oncology, and reliance on the success of its AI-driven platform.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
2.76
Dividend Yield
-
Revenue TTM
7.49M
Revenue Per Share
0.94
Gross Profit TTM
7.49M
Debt / Equity
0.44
ROE
-109.86%
Net Debt
-15.73M
ROCE
-38.35%
Diluted EPS TTM
-0.49

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -8.64M -11.36M -22.95M -23.94M -24.71M
Net income -7.73M -10.57M -22.16M -23.17M -24.53M
Selling general administrative 6.49M 7.32M 10.08M 8.21M 6.25M
Selling and marketing expenses - - 0.02M - -
Gross profit 7.53M 3.34M 0.07M -0.57M -0.34M
Reconciled depreciation 0.61M 0.61M 0.61M 0.57M 0.34M
Ebit -9.26M -10.39M -22.23M -25.26M -25.83M
Ebitda -8.65M -9.79M -21.62M -22.43M -23.80M
Depreciation and amortization 0.62M 0.61M 0.62M 2.83M 2.04M
Operating income -9.26M -14.73M -22.23M -25.26M -25.83M
Other operating expenses 16.81M 18.08M 22.30M 25.26M 25.83M
Interest expense 0.88M 0.96M 0.90M 1.51M 0.92M
Tax provision -0.91M -0.79M -0.79M -0.77M -0.18M
Interest income 0.30M 0.25M 2.34M 2.83M 2.04M
Net interest income 1.99M -0.71M -3.01M 1.32M 1.12M
Income tax expense -0.91M -0.79M -0.79M -0.77M -0.18M
Total revenue 7.55M 3.34M 0.07M 0.00M 0.00M
Total operating expenses 16.76M 18.08M 21.69M 25.26M 25.83M
Cost of revenue - - - 0.57M 0.34M
Total other income expense net 0.62M 3.38M -0.72M 1.32M 1.12M
Net income from continuing ops -7.71M -10.57M -24.47M -23.17M -24.53M
Net income applicable to common shares - - - - -24.53M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 28.41M 12.48M 12.89M -58.94M 40.16M
Intangible assets - - - - 0.09M
Other current assets 0.62M 1.85M 1.69M - 2.54M
Total liab 11.37M 14.14M 17.62M 13.72M 7.73M
Total stockholder equity 17.04M -1.65M -4.73M -72.66M -50.43M
Other current liab 1.52M 0.93M 3.91M 1.37M 1.03M
Common stock 15.79M 10.52M 5.90M 3.89M 3.75M
Capital stock 15.79M 10.52M 5.90M 3.89M 3.75M
Retained earnings -126.24M -118.54M -107.97M -72.66M -50.43M
Other liab - - - - 0.15M
Other assets - - - -77.95M 0.19M
Cash 23.23M 5.05M 5.58M 13.18M 32.17M
Total current liabilities 4.26M 4.37M 7.08M 3.76M 4.32M
Current deferred revenue - - 0.00M - -
Net debt -15.73M 5.05M 5.29M -10.93M -28.48M
Short term debt 0.55M 0.47M 0.48M 0.30M 0.44M
Short long term debt 0.19M 0.16M 0.16M 0.14M 0.13M
Short long term debt total 7.50M 10.10M 10.87M 2.25M 3.69M
Other stockholder equity 120.73M 109.97M 87.45M -0.23M -82.87M
Property plant equipment - - - - 5.17M
Total current assets 24.90M 8.77M 8.35M 13.97M 34.70M
Net tangible assets - - - - 16.55M
Net receivables 1.05M 1.86M 1.07M 0.79M 1.90M
Long term debt 5.35M 8.01M 8.49M 7.86M 1.04M
Inventory - - - - -1.90M
Accounts payable 2.19M 2.97M 2.69M 2.08M 2.85M
Accumulated other comprehensive income 6.76M -3.60M 9.89M -3.65M 79.11M
Non currrent assets other 0.18M 0.16M 0.17M 0.36M 0.09M
Non current assets total 3.51M 3.72M 4.54M 5.04M 5.46M
Capital lease obligations 1.97M 1.93M 2.22M 2.25M 2.52M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -0.00M -0.00M -0.09M -0.27M -1.33M
Change to liabilities - - - - -0.65M
Total cashflows from investing activities -0.01M -0.00M - - -1.33M
Net borrowings -0.75M -1.14M - - -0.29M
Total cash from financing activities 22.48M 13.13M 10.71M 7.85M 49.80M
Change to operating activities - - - - 0.02M
Net income -7.73M -10.57M -22.16M -23.17M -24.53M
Change in cash 17.28M 0.37M -7.60M -18.98M 26.33M
Begin period cash flow 5.95M 5.58M 13.18M 32.17M 5.83M
End period cash flow 23.23M 5.95M 5.58M 13.18M 32.17M
Total cash from operating activities -6.65M -12.94M -17.72M -25.77M -21.93M
Issuance of capital stock 23.16M 16.55M 9.17M 0.43M 53.85M
Depreciation 0.62M 0.61M 0.62M 0.57M 0.34M
Other cashflows from investing activities - - - - 0.03M
Change to inventory - - 0.00M 1.49M -1.86M
Change to account receivables 0.18M 0.37M 1.11M -1.49M 1.86M
Other cashflows from financing activities -0.35M -2.29M -0.43M 0.43M -3.76M
Change to netincome - - - - 1.02M
Capital expenditures 0.01M 0.00M 0.09M 0.29M 1.36M
Change in working capital -0.14M 0.52M 1.56M -2.88M 1.24M
Stock based compensation 0.31M 0.36M 0.48M 0.94M 1.38M
Other non cash items 0.61M -3.04M 2.77M -0.24M -0.17M
Free cash flow -6.66M -12.94M -17.81M -26.07M -23.29M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
EVAX
Evaxion Biotech AS		 0.24
8.70%		 3.00 - 3.57 3.66 2.94 2.83 -0.59
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Evaxion Biotech AS

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Dr. Neergaards Vej, Horsholm, Denmark, 2970

45 53 53 18 50

https://evaxion.ai

46

Name Title Year Born
Dr. Niels Iversen Moeller M.D. Co-Founder, VP of Bus. & Director 1979
Mr. Andreas Holm Mattsson Co-Founder and Chief AI & Culture Officer 1976
Dr. Birgitte Rono Ph.D. Chief Scientific Officer 1976
Dr. Erik Deichmann Heegaard DMSC, M.D., Ph.D. Chief Medical Officer 1968
Dr. Per Norlen Chief Exec. Officer 1970
Mr. Bo Lokke Karmark Chief Financial Officer 1965
Mr. Jesper Nyegaard Nissen Chief Operating Officer 1970
Dr. Jürgen Langhärig EMBA, Ph.D. Head of Bus. Devel. & Member of Advisory Board NA
Mr. Christian Kanstrup M.Sc. Chief Executive Officer 1972
Mr. Jesper Nyegaard Nissen M.Sc. Interim CFO & COO 1970

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…